Literature DB >> 19494728

Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis.

Liam G Johnson1, Kelly E Collier, Dylan J Edwards, Danielle L Philippe, Peter R Eastwood, Susan E Walters, Gary W Thickbroom, Frank L Mastaglia.   

Abstract

OBJECTIVES: The study aimed to investigate the effects of a combined functional and aerobic exercise program on aerobic capacity, muscle strength, and functional mobility in a group of patients with sporadic inclusion body myositis (IBM).
METHODS: Aerobic capacity, muscle strength, and functional capacity assessments were conducted on 7 participants with sporadic IBM before and after a 12-week exercise program, which included resistance exercises and aerobic stationary cycling 3 times per week on alternative days.
RESULTS: Aerobic capacity of the group increased significantly by 38%, and significant strength improvements were observed in 4 of the muscle groups tested (P < 0.05). The exercise program was well tolerated, and there was no significant change in the serum creatine kinase level after the exercise period.
CONCLUSIONS: An aerobic exercise program can be safely tolerated by patients with sporadic IBM and can improve aerobic capacity and muscle strength when combined with resistance training. These findings indicate that aerobic and functional muscle strengthening exercise should be considered in the management of patients with IBM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494728     DOI: 10.1097/CND.0b013e3181a23c86

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  28 in total

Review 1.  The relevance of applying exercise training principles when designing therapeutic interventions for patients with inflammatory myopathies: a systematic review.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Bernadette C Tobler-Ammann; Britta Maurer; Ruud H Knols
Journal:  Rheumatol Int       Date:  2015-08-14       Impact factor: 2.631

Review 2.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

3.  Diagnosis and treatment of inflammatory myopathy: issues and management.

Authors:  Christine Castro; Mark Gourley
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 4.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 5.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 6.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 7.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

8.  Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors:  Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

Review 9.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 10.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.